Stage
No active trials
Next date
None yet
Trials
0 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Amyotrophic Lateral Sclerosis (2 trials), Chronic Obstructive Pulmonary Disease (COPD), Mobility Limitation
- Main trialPhase 3
- “The purpose of this study is to assess the long-term safety and tolerability of reldesemtiv in patients with ALS who have successfully completed dosing in the Phase 3 clinical trial, CY 5031 (also known as COURAGE-ALS)”In the company’s words, NCT05442775 on ClinicalTrials.gov
- Other names
- CK-2127107
Other drugs for Amyotrophic Lateral Sclerosis
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Terminated | 7 Jun 2023 | A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) | |
| Phase 3Terminated | 18 Jul 2023 | A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 2Completed | 8 Jun 2018 | A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease | |
| Phase 1Terminated | 10 Oct 2018 | A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026